Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd (301126) Fair Value & Analysis
Healthcare · CN · Market cap 1.9B CNY
Risks
Fair value as of: Aug 13, 2026
From 6 valuation models · updated 9 days ago
Share price +25.4% over the past month.
Below-average quality, and screening another 51% overvalued on our models.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (¥9.17). The favourable scenario is already priced in.
- Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The model range is unusually wide (¥0.9920 to ¥9.17). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
56‑month range ¥6.78 – ¥35.81 · fair‑value band ¥0.9920 – ¥9.17 · the ¥10.17 price screens above the ¥4.96 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd (301126) currently trades at ¥10.17, while our model-based Fair Value estimate is ¥4.96, implying the stock looks roughly 51.2% overvalued today. The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd generated revenue of 5.2B CNY at a net margin of -4.6%. Revenue grew 6.5% year over year. It earns a return on equity of -13.2%. Net debt stands at 2.4B CNY. Fundamentals as of Aug 13, 2026
Our scenario range runs from ¥0.9920 (bear case) to ¥9.17 (bull case); at ¥10.17, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 32% below its 52-week high and 10% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at -51%, 301126 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 6 models by family
Widest divergence: Multiples (¥8.98) versus Earnings-Based (¥3.74). Highest evidence: ROIC Compounder (72).
Notify me when 301126 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 30 · Market factors (momentum, volatility) 30
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd engages in the wholesale and retail of pharmaceuticals products in China. It provides raw materials, biological products, chemical drugs, Chinese herbal medicines, medical devices, and other products.
Full company description
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd engages in the wholesale and retail of pharmaceuticals products in China. It provides raw materials, biological products, chemical drugs, Chinese herbal medicines, medical devices, and other products. The company also offers Chinese patent medicines in the form of granules, capsules, particles, tablets, slices, and pills; foods, such as beverages, drinks, and probiotic beverages; and cleansing and care products. In addition, it provides pharmaceutical logistics services; and operates reproductive hospitals. The company was formerly known as Hunan Tongjian Pharmacy CO., LTD and changed its name to Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd in August 2016. Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd was founded in 2002 and is headquartered in Changsha, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd reported revenue of ¥5.1B in FY2025 versus ¥2.6B in FY2021, a compound +18.7%/yr. Reported net income was −¥242M in FY2025.
301126 screens 51% overvalued. Compare with JD Health International Inc →
Peer Group
Pharmaceutical Retailers · 64 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Pharmaceutical Retailers median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc 6618 | HK$38.86 | HK$33.31 | -14% |
| Raia Drogasil S.A RADL3 | R$18.00 | R$15.58 | -13% |
| Alibaba Health Information Technology Limited 0241 | HK$3.26 | HK$2.04 | -37% |
| Yifeng Pharmacy Chain Co 603939 | ¥24.03 | ¥29.07 | +21% |
| DaShenLin Pharmaceutical Group 603233 | ¥18.14 | ¥23.86 | +32% |
| Corporativo Fragua, S.A. FRAGUAB | 463.00 MXN | 726.02 MXN | +57% |
| MedPlus Health Services Limited MEDPLUS | ₹656.80 | ₹191.97 | -71% |
| LBX Pharmacy Chain Joint Stock Company 603883 | ¥13.44 | ¥10.57 | -21% |
| Yixintang Pharmaceutical Group 002727 | ¥11.61 | ¥9.45 | -19% |
| Anhui Huaren Health Pharmaceutical Co 301408 | ¥16.31 | ¥10.05 | -38% |
Compare Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd (301126) overvalued or undervalued?
What is the fair value of 301126?
What is the quality score of 301126?
What is the revenue of Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd (301126)?
What is the net profit margin of 301126?
Does Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.